UK Markets open in 1 hr 13 mins
  • NIKKEI 225

    29,753.26
    +214.53 (+0.73%)
     
  • HANG SENG

    28,523.86
    +70.58 (+0.25%)
     
  • CRUDE OIL

    59.89
    +0.19 (+0.32%)
     
  • GOLD FUTURES

    1,725.40
    -7.30 (-0.42%)
     
  • DOW

    33,745.40
    -55.20 (-0.16%)
     
  • BTC-GBP

    44,256.32
    +185.14 (+0.42%)
     
  • CMC Crypto 200

    1,298.96
    +4.37 (+0.34%)
     
  • Nasdaq

    13,850.00
    -50.19 (-0.36%)
     
  • ^FTAS

    3,933.89
    -15.62 (-0.40%)
     

Global CNS Therapeutics Industry

ReportLinker
·10-min read

Abstract: - The global market for CNS Therapeutics is projected to reach US$137. 7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders.

New York, April 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global CNS Therapeutics Industry" - https://www.reportlinker.com/p06050565/?utm_source=GNW
Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase. Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others. The need of the hour is innovation in developing more potent drugs and therapies. One of the reasons for the slower development of safe and effective drugs for neurology is the fact that the human brain is one of the most complex and highly organized organs in the universe. The brain is a highly sophisticated piece of organic system perfected over millions of years of evolution. Scientists continue to struggle to fathom the complex interaction of chemicals and neurons in the brain. Investments in drug development in neurology is risky since certain diseases like neuropsychiatric diseases are difficult to target, are poorly defined, cannot be easily assayed, and pose challenges in efficiently validating clinical efficiency of drugs during clinical trials as most diseases progress slowly and develop over the years.
- Strong opportunities for CNS focussed drugs therefore exists and compounding this need is the rapidly aging population and a parallel rise in Parkinson`s, Alzheimer`s, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders. The scenario has created a healthy global pipeline of late stage drugs and the market is expected to benefit from rising acceptance of new therapies and new classes of drugs; increased demand for combination therapies; growing use of generics; and launch of new Alzheimer`s drugs including anti-amyloid proteins, cholinergic and nicotine receptor agonists, neuro protective drugs, vaccines and GABA receptor modulators. Better understanding of the electrochemical processes of the brain and development of disease-modifying therapies is driving growth in the antiepileptic drugs market. Combination CNS Therapies are especially gaining prominence for their ability to target multiple pathologic processes simultaneously. Volume of CNS prescriptions for chronic pain and psychiatric disorders will grow in the coming years as the burden of mental illnesses intensifies as a result of lifestyle and societal changes and physiological stress. The growing focus on healthcare cost containment and rationalization and legislation of policies that encourage physician prescription of generic drugs will encourage sales of generic CNS medications. A key trend in the market is pharma companies` efforts to restrategize CNS drug development, which still continues to cost significantly higher than development costs in other therapeutic areas. Increased use of contract research organization services; and predictive planning to prevent late stage drug failure are few of the strategies adopted to infuse vigor in the CNS drug development space. The United States and Europe represent large markets worldwide with a combined share of 70% of the market. China ranks as the fastest growing market with a CAGR of 7.3% over the analysis period supported by factors such as changing social structures and increased risk of developing psychiatric disorders such as schizophrenia, sleep disorders, depression and anxiety; growing literacy rates, improved awareness and gradual reduction in the stigma associated with neurological disorders; and government policy led development of healthcare delivery systems.

- Select Competitors (Total 181 Featured) -

  • AbbVie Inc.

  • Alkermes Plc.

  • Allergan Plc.

  • AstraZeneca Plc.

  • Bristol-Myers Squibb

  • Eisai Co., Ltd.

  • Eli Lilly and Co.

  • Endo Pharmaceuticals Inc.

  • F. Hoffmann-La Roche Ltd.

  • GlaxoSmithKline Plc

  • H. Lundbeck A/S

  • Janssen Pharmaceuticals Inc.

  • Merck & Co., Inc.

  • Neurocrine Biosciences, Inc.

  • Novartis AG

  • Otsuka Pharmaceutical Co. Ltd.

  • Pfizer Inc.

  • Purdue Pharma L.P.

  • Sanofi

  • Shire Plc

  • Sumitomo Dainippon Pharma Co., Ltd.

  • Takeda Pharmaceutical Co., Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • UCB Group




Read the full report: https://www.reportlinker.com/p06050565/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Healthcare Cloud
Computing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 2: World 7-Year Perspective for Healthcare Cloud
Computing by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2020 & 2027

Table 3: World Current & Future Analysis for SaaS by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 4: World 7-Year Perspective for SaaS by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World for Years 2020 &
2027

Table 5: World Current & Future Analysis for IaaS by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 6: World 7-Year Perspective for IaaS by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World for Years 2020 &
2027

Table 7: World Current & Future Analysis for PaaS by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 8: World 7-Year Perspective for PaaS by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World for Years 2020 &
2027

III. MARKET ANALYSIS

UNITED STATES
Table 9: USA Current & Future Analysis for Healthcare Cloud
Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 10: USA 7-Year Perspective for Healthcare Cloud Computing
by Service - Percentage Breakdown of Value Sales for SaaS, IaaS
and PaaS for the Years 2020 & 2027

CANADA
Table 11: Canada Current & Future Analysis for Healthcare Cloud
Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 12: Canada 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

JAPAN
Table 13: Japan Current & Future Analysis for Healthcare Cloud
Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 14: Japan 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

CHINA
Table 15: China Current & Future Analysis for Healthcare Cloud
Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 16: China 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

EUROPE
Table 17: Europe Current & Future Analysis for Healthcare Cloud
Computing by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2020 through 2027 and % CAGR

Table 18: Europe 7-Year Perspective for Healthcare Cloud
Computing by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2020 & 2027

Table 19: Europe Current & Future Analysis for Healthcare Cloud
Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 20: Europe 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

FRANCE
Table 21: France Current & Future Analysis for Healthcare Cloud
Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 22: France 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

GERMANY
Table 23: Germany Current & Future Analysis for Healthcare
Cloud Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 24: Germany 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

ITALY
Table 25: Italy Current & Future Analysis for Healthcare Cloud
Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 26: Italy 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

UNITED KINGDOM
Table 27: UK Current & Future Analysis for Healthcare Cloud
Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 28: UK 7-Year Perspective for Healthcare Cloud Computing
by Service - Percentage Breakdown of Value Sales for SaaS, IaaS
and PaaS for the Years 2020 & 2027

REST OF EUROPE
Table 29: Rest of Europe Current & Future Analysis for
Healthcare Cloud Computing by Service - SaaS, IaaS and PaaS -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 30: Rest of Europe 7-Year Perspective for Healthcare
Cloud Computing by Service - Percentage Breakdown of Value
Sales for SaaS, IaaS and PaaS for the Years 2020 & 2027

ASIA-PACIFIC
Table 31: Asia-Pacific Current & Future Analysis for Healthcare
Cloud Computing by Service - SaaS, IaaS and PaaS - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 32: Asia-Pacific 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

REST OF WORLD
Table 33: Rest of World Current & Future Analysis for
Healthcare Cloud Computing by Service - SaaS, IaaS and PaaS -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 34: Rest of World 7-Year Perspective for Healthcare Cloud
Computing by Service - Percentage Breakdown of Value Sales for
SaaS, IaaS and PaaS for the Years 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 59
Read the full report: https://www.reportlinker.com/p06050565/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001